Associations between HLA-B27 subtypes and outcomes in Thai children with enthesitis-related arthritis
6
Issued Date
2022-01-01
Resource Type
ISSN
07703198
eISSN
14349949
Scopus ID
2-s2.0-85111890118
Pubmed ID
34355293
Journal Title
Clinical Rheumatology
Volume
41
Issue
1
Start Page
203
End Page
212
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Rheumatology Vol.41 No.1 (2022) , 203-212
Suggested Citation
Vilaiyuk S. Associations between HLA-B27 subtypes and outcomes in Thai children with enthesitis-related arthritis. Clinical Rheumatology Vol.41 No.1 (2022) , 203-212. 212. doi:10.1007/s10067-021-05875-5 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/86765
Title
Associations between HLA-B27 subtypes and outcomes in Thai children with enthesitis-related arthritis
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Objective: Expression of human leukocyte antigen B27 (HLA-B27) has been identified as a predictor of severe disease in enthesitis-related arthritis (ERA) patients. However, the associations between HLA-B27 subtypes and outcomes of this disease are still unclear. Here, we examined the distributions of HLA-B27 subtypes among ERA patients and the associations with disease outcomes. Methods: This was a historical cohort study of ERA patients. Patients were followed from diagnosis to the most recent visit. Relationships between outcomes and the HLA-B27 subtype were assessed by mixed-effect regression, Kaplan–Meier survival, and Cox proportional hazards regression analyses. Results: Of the 66 ERA patients, 50 HLA-B27-positive (86% male) and 16 HLA-B27-negative (69% male) patients were included in this study. Patients with HLA-B27-positive were classified into HLA-B*27:04-positive (84%), including combined HLA-B*27:04 and HLA-B*27:07 (2%), and HLA-B*27:04-negative (16%), including HLA-B*27:05 (10%), HLA-B*27:06 (2%), HLA-B*27:07 (2%), and HLA-B*27:15 (2%). HLA-B*27:04-positive (83.3%) and HLA-B*27:04-negative patients (100%) had refractory disease more than HLA-B27-negative patients (37.5%, p = 0.001). HLA-B*27:04-negative patients (57%, 1.73 years) had relapsing disease more and earlier than HLA-B*27:04-positive (35%, 5.54 years) and HLA-B27-negative patients (40%, 6.92 years; p < 0.001). Furthermore, HLA-B*27:04-negative was predictors of refractory disease (HR 4.56, 95%CI 1.40–14.87; p = 0.012) and relapsing disease (HR 3.80, 95% CI 1.18–12.30; p = 0.026). The duration before anti-tumor necrosis factor treatment initiation > 1 year was also a predictor of refractory disease (HR 116.08, 95% CI 14.67–918.26; p < 0.001). Conclusion: HLA-B*27:04 was the most common HLA-B27 subtype in Thai ERA patients. HLA-B*27:04-negative was associated with more unfavorable outcomes than HLA-B*27:04-positive and HLA-B27-negative patients.Key Points• Most ERA patients in Thailand had HLA-B27-positive, and HLA-B*27:04 was the most common HLA-B27 allele in these patients.• The outcomes of ERA were associated with the presence of HLA-B27 and its subtypes.• HLA-B*27:04-negative patients had unfavorable outcomes, including refractory and relapsing disease, compared to HLA-B*27:04-positive and HLA-B27-negative patients.